If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,750.00    75.00 (1.60%)
Bid:
4,700.00
Ask:
4,800.00
Spread: 100.00 (2.128%)
Market Cap: £316.38m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Acquisition

19 Mar 2010 07:00

RNS Number : 8335I
Judges Scientific PLC
19 March 2010
Β 

ο»Ώ

19 March 2010

Β 

JUDGES SCIENTIFIC plc

("Judges Scientific", "Judges" or the "Company")

Β 

ACQUISITION OF SIRCAL INSTRUMENTS (UK) LIMITED

Β 

Judges Scientific, the parent company of a group that specialises in the design, manufacture and sale of scientific instruments, announces that its wholly-owned subsidiary, Fire Testing Technology Limited ("FTT"), has today completed the acquisition of the entire issued share capital of Sircal Instruments (UK) Limited ("Sircal") for a consideration of Β£1 million, payable in cash. An additional payment will be made to reflect the working capital available at completion in excess of the ongoing requirements of the business. Such payment is expected by Judges to be more than covered by the cash inherited at completion.

Β 

Sircal designs, manufactures and distributes rare gas purifiers for use in metals analysis utilising the Arc Spark spectrometry technique. This technique provides qualitative and quantitative analysis of a metallic sample. The process does not require complicated sample preparation and is widely used in the metals industry. When accurate measurements are required, the process must be carried out in an environment free from the type of contaminants that would affect the performance of the metal; the test is therefore conducted in an atmosphere of rare gas (usually argon) that is itself sufficiently free from contamination.Β  The function of the purifier is to achieve the required rare gas purity.

Β 

The principal markets for Arc Spark spectrometry relate to the production of speciality steel, cast iron, aluminium and other non-ferrous metals. These are the markets served by Sircal, directly or through OEM customers who manufacture spectrometers. In contrast to the majority of Judges' existing operations, Sircal is largely reliant on the private sector. The vast majority of Sircal's production is exported, as is the case with the other businesses in the Judges group. Judges believes the company to be a clear world leader in the market for purifiers used in metals analysis. Sircal's revenues include a significant element of consumables (approximately 30% in the last financial year).

Β 

The two vendors were among the founders of Sircal in 1981 and since 2004 have been its only employees. It has been agreed that they will assist Judges during a three-month transition period while the business is transferred to FTT's premises, where it will be operated by the FTT team. Judges Scientific will not assume responsibility for Sircal's existing premises. The Board of Judges believes that risk is reduced in such an acquisition where the purchaser does not inherit responsibility for staff or premises.

Β 

Sircal's unaudited accounts for the year ended 30 September 2009 show sales of Β£785,000 on which the company generated operating profits of Β£337,000. Net tangible assets at 30 September 2009 amounted to Β£423,000, including Β£458,000 of cash and cash equivalents. Sircal's operating profits figure of Β£337,000 reflects the way the business has been operated historically; the Board of Judges believes that, had the business been owned by the Company during that period, it would have generated a contribution in the order of Β£270,000. The Board expects the acquisition to be earnings-enhancing in the current year.

Β 

The Bank of Scotland has made available to Judges a Β£1 million extension to the Β£3 million term loan which was arranged in June 2009 to finance the acquisition of Quorum Technologies Limited and to refinance the Company's outstanding borrowings at that time. In addition, a Β£500,000 overdraft facility continues to be available to the Company.

Β 

Alex Hambro, Chairman of Judges, commented: "I am delighted that we have purchased another niche instrument business and that we have been able to do so without issuing shares. We regard our level of indebtedness as prudent, Sircal comes without the usual fixed cost commitments and the nature of its customer base will serve to moderate the Group's current bias towards public sector markets. This acquisition should prove earnings-enhancing in the current year, while providing an unusually low level of added risk".

Β 

Enquiries:

Β 

David Cicurel, CEO, Judges Scientific: Tel: 01342 323 600

Β 

Pascal Keane, Shore Capital: Tel: 020 7408 4090

Β 

Melvyn Marckus, Cardew Group: Tel: 07775 896 491

Β 

Web sites:

Β 

Judges Scientific: www.judges.uk.com

Β 

Sircal: www.sircal.co.uk

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ACQUWRWRRUAOAAR
Date   Source Headline
29th Jan 20217:00 amRNSTotal Voting Rights
19th Jan 202111:57 amRNSDirector/PDMR Shareholding
8th Jan 20219:31 amRNSGrant of Options
7th Jan 20212:30 pmRNSDirector/PDMR Shareholding
7th Jan 20217:00 amRNSTrading Statement and Notice of Final Results
31st Dec 20207:00 amRNSTotal Voting Rights
10th Dec 20207:00 amRNSDirector/PDMR Shareholding
16th Nov 20207:00 amRNSBlock listing Interim Review
12th Nov 20207:00 amRNSCORRECTION: Director/PDMR Shareholding
11th Nov 20204:48 pmRNSDirector/PDMR Shareholding
10th Nov 20207:00 amRNSDirector/PDMR Shareholding
3rd Nov 20207:00 amRNSGrant of Options
26th Oct 20205:16 pmRNSExercise of Options and Director Dealing
19th Oct 20204:38 pmRNSDirector/PDMR Shareholding
19th Oct 20207:00 amRNSAcquisition of Korvus Technology Ltd
7th Oct 20209:33 amRNSDirector/PDMR Shareholding
22nd Sep 20207:00 amRNSInterim Results
16th Sep 20202:17 pmRNSHolding(s) in Company
10th Sep 202011:25 amRNSDirector/PDMR Shareholding
10th Sep 20207:00 amRNSBoard Change
1st Sep 20209:48 amRNSTotal Voting Rights
11th Aug 20208:24 amRNSDirector/PDMR Shareholding
31st Jul 20207:00 amRNSTotal Voting Rights
21st Jul 20207:00 amRNSTrading Update and Notice of Interim Results
7th Jul 20202:28 pmRNSDirector/PDMR Shareholding
30th Jun 20207:00 amRNSTotal Voting Rights
8th Jun 20204:03 pmRNSDirector/PDMR Shareholding
2nd Jun 20207:00 amRNSTotal Voting Rights
29th May 20207:00 amRNSAcquisition of Heath Scientific Company Limited
20th May 20201:55 pmRNSResult of AGM
20th May 20207:00 amRNSAGM Update
15th May 20208:53 amRNSBlock listing Interim Review
14th May 20209:52 amRNSAGM Q&A
7th May 20209:59 amRNSDirector/PDMR Shareholding
30th Apr 20209:52 amRNSTotal Voting Rights
28th Apr 20207:00 amRNSNotice of AGM
8th Apr 202010:23 amRNSDirector/PDMR Shareholding
31st Mar 202011:10 amRNSTotal Voting Rights
18th Mar 20207:00 amRNSFinal Results
17th Mar 202011:05 amRNSSecond Price Monitoring Extn
17th Mar 202011:00 amRNSPrice Monitoring Extension
10th Mar 20208:55 amRNSDirector/PDMR Shareholding
24th Feb 20207:00 amRNSStatement regarding COVID-19
7th Feb 20207:00 amRNSDirector/PDMR Shareholding
31st Jan 202010:46 amRNSBlocklisting Application and Total Voting Rights
16th Jan 20203:18 pmRNSExercise of Options and Director Dealing
16th Jan 20207:00 amRNSTrading Statement and Notice of Final Results
13th Jan 20209:37 amRNSDirector/PDMR Shareholding
2nd Jan 20201:42 pmRNSTotal Voting Rights
18th Dec 20198:49 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.